APO-IMATINIB APO-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. APO-IMATINIB is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy). APO-IMATINIB is...Read More
The overarching themes for us of this years ASH is that there is a high percentage of more serious types of adverse events/side effects that are occurring with the newer TKI’s, but there is also much excitement towards increasing the number of patients who can be successfully managed off treatment as well. With regards to...Read More
Hello Everyone and welcome to our tenth annual coverage of the ASH meeting. This Year’s ASH is taking place in San Francisco California. 1st report: Minimal Residual Disease in CML – by Dr. M Mauro.Read More
ASH 2012 – Exciting as always! From the moment I stepped on to the plan my mind is preoccupied with all things related to ASH. Who will we meet there, what exciting new information will we learn. But, mostly my mind always turns back to my very first ASH in 2004 – an early Christmas...Read More
Bill C-64 was announced by the Liberal and NDP Government on February 29, 2024. To read the entire C-64 click on the link below: Bill C-64 An Act Respecting Pharmacare To See the progress of Bill C-64 The Current status is it has had a second reading in the Senate. Here is a brief critical...Read More
Done at diagnosis, it is the most precise way to diagnose CML as well as provide helpful information about your specific case of CML. An analysis of bone marrow samples confirms the presence of the Philadelphia chromosome and if other abnormalities are present. The bone marrow biopsy may be referred ot as a BMA/BMB. It...Read More
BOSULIF (™) (bosutinib) BOSULIF (bosutinib), indicated for, the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy, and for whom subsequent treatment with imatinib, nilotinib and dasatinib is not clinically appropriate. To read the announcement from Pfizer regarding the...Read More
Health Canada CONDITIONALLY approves BOSULIF – a new medication for chronic myelogenous leukemiaApproval provides new treatment option for Canadians suffering from rare cancer SANTÉ CANADA APPROUVE CONDITIONNELLEMENT L’EMPLOI DE BOSULIF – UN NOUVEAU MÉDICAMENT CONTRE LA LEUCÉMIE MYÉLOÏDE CHRONIQUELes Canadiens bénéficient ainsi d’une nouvelle option de traitement pour un cancer rare Read More
The CML Society of Canada has been invited to provide input to the Pan Canadian Oncology Drug Review regarding the process that will eventually determine whether iClusig will be reimbursed through the various provincial bodies. The Pan Canadian Oncology Drug Review analyzes information from Oncologists, Health Care Economists, Patients and the manufacturers. The outcome is...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
